ABT · News · 20260814N
Diagnostics Collaboration Expansion
ABBOTT LABORATORIES · 2026-08-14 · Importance 31 · Surprise 42 · In source text
Abbott will sell Freenome’s SimpleScreen CRC colorectal-cancer blood test in the United States. Freenome received FDA breakthrough-device designation for its SimpleScreen Lung test for high-risk individuals. The two tests use a blood-based platform combining DNA-methylation patterns with AI algorithms, expanding Abbott’s commercial diagnostics offering.
Key facts
- Abbott Laboratories will sell Freenome's SimpleScreen CRC test in the US. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Abbott Laboratories will sell Freenome's SimpleScreen CRC test in the US. |